安全性の懸念にもかかわらず、ペプチドの規制緩和をFDAが議論
原題: FDA to discuss easing restrictions on peptides despite safety concerns
分析結果
- カテゴリ
- 医療
- 重要度
- 49
- トレンドスコア
- 12
- 要約
- FDAは、ペプチドに関する規制の緩和を検討する予定です。これに対して、安全性に関する懸念が存在しています。ペプチドは医療や美容分野での利用が期待されていますが、その安全性や効果についての議論が続いています。FDAの会議では、これらの懸念を踏まえた上で、今後の方針が決定される見込みです。
- キーワード
Committee will meet in July to discuss peptides now sold in gray market despite limited evidence of safety and efficacy Advisers to the Food and Drug Administration (FDA) will soon hold a meeting about whether to ease restrictions on access to some research peptides, a group of drugs with a zealous following and thin evidence to support them. If restrictions are eased, US compounding pharmacies would be able to produce and fill prescriptions for Americans – a change that would effectively legalize a thriving gray market. Continue reading... Committee will meet in July to discuss peptides now sold in gray market despite limited evidence of safety and efficacy Advisers to the Food and Drug Administration (FDA) will soon hold a meeting about whether to ease restrictions on access to some research peptides, a group of drugs with a zealous following and thin evidence to support them. If restrictions are eased, US compounding pharmacies would be able to produce and fill prescriptions for Americans – a change that would effectively legalize a thriving gray market. Continue reading...